Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	nuclear retinoic acid receptor binding	PRAMEF5 NCOR1 PRMT2 PRAMEF26 LRIF1 PRAMEF6	5.98e-07	55	111	6	GO:0042974
GeneOntologyMolecularFunction	nuclear receptor binding	PRAMEF5 STAT3 NCOR1 PRMT2 PRAMEF26 LRIF1 PRAMEF6	8.44e-05	187	111	7	GO:0016922
GeneOntologyMolecularFunction	peptide-lysine-N-acetyltransferase activity	JADE1 ESCO2 BRCA2 PHF10	2.48e-04	55	111	4	GO:0061733
GeneOntologyMolecularFunction	peptide N-acetyltransferase activity	JADE1 ESCO2 BRCA2 PHF10	3.47e-04	60	111	4	GO:0034212
GeneOntologyCellularComponent	eukaryotic translation initiation factor 3 complex	EIF3E EIF3L EIF3G	8.18e-05	16	113	3	GO:0005852
GeneOntologyCellularComponent	eukaryotic 48S preinitiation complex	EIF3E EIF3L EIF3G	1.18e-04	18	113	3	GO:0033290
GeneOntologyCellularComponent	eukaryotic 43S preinitiation complex	EIF3E EIF3L EIF3G	1.40e-04	19	113	3	GO:0016282
GeneOntologyCellularComponent	translation preinitiation complex	EIF3E EIF3L EIF3G	1.64e-04	20	113	3	GO:0070993
GeneOntologyCellularComponent	symmetric, GABA-ergic, inhibitory synapse	NLGN4Y NLGN4X	1.73e-04	4	113	2	GO:0098983
Domain	LRRC37AB_C	LRRC37A3 LRRC37A2 LRRC37A	7.70e-07	4	109	3	PF14914
Domain	LRRC37_N	LRRC37A3 LRRC37A2 LRRC37A	7.70e-07	4	109	3	IPR032754
Domain	LRRC37AB_C	LRRC37A3 LRRC37A2 LRRC37A	7.70e-07	4	109	3	IPR029423
Domain	LRRC37	LRRC37A3 LRRC37A2 LRRC37A	7.70e-07	4	109	3	PF15779
Domain	LRRC37A/B-like	LRRC37A3 LRRC37A2 LRRC37A	7.70e-07	4	109	3	IPR015753
Domain	NLGN4	NLGN4Y NLGN4X	3.37e-05	2	109	2	IPR030025
Domain	PRMT5	PRMT5 PRMT2	1.01e-04	3	109	2	PF05185
Domain	Arg_MeTrfase_PRMT5	PRMT5 PRMT2	1.01e-04	3	109	2	IPR007857
Domain	Nlgn	NLGN4Y NLGN4X	3.34e-04	5	109	2	IPR000460
Domain	-	PRAMEF5 NLRP7 LRRC37A3 LRRC37A2 LRRIQ4 LRRC4 LRRC37A PRAMEF6	5.89e-04	321	109	8	3.80.10.10
Domain	L_dom-like	PRAMEF5 NLRP7 LRRC37A3 LRRC37A2 LRRIQ4 LRRC4 LRRC37A PRAMEF6	6.79e-04	328	109	8	IPR032675
Domain	Plectin_repeat	EVPL PPL	6.95e-04	7	109	2	IPR001101
Domain	Plectin	EVPL PPL	6.95e-04	7	109	2	PF00681
Domain	PLEC	EVPL PPL	6.95e-04	7	109	2	SM00250
Domain	ig	PECAM1 SIGLEC14 SIGLEC5 LRRC4 KDR VCAM1	8.71e-04	190	109	6	PF00047
Domain	Immunoglobulin	PECAM1 SIGLEC14 SIGLEC5 LRRC4 KDR VCAM1	8.71e-04	190	109	6	IPR013151
Domain	PKD/Chitinase_dom	KIAA0319L GPNMB	1.18e-03	9	109	2	IPR022409
Domain	SAM_MT_PRMT	PRMT5 PRMT2	1.18e-03	9	109	2	PS51678
Domain	PKD	KIAA0319L GPNMB	1.18e-03	9	109	2	SM00089
Domain	Arg_MeTrfase	PRMT5 PRMT2	1.18e-03	9	109	2	IPR025799
Domain	PKD	KIAA0319L GPNMB	1.79e-03	11	109	2	PS50093
Domain	PKD_dom	KIAA0319L GPNMB	1.79e-03	11	109	2	IPR000601
Domain	-	KIAA0319L GPNMB	1.79e-03	11	109	2	2.60.40.670
Domain	Carboxylesterase_B_CS	NLGN4Y NLGN4X	2.52e-03	13	109	2	IPR019819
Domain	IGc2	PECAM1 SIGLEC14 SIGLEC5 LRRC4 KDR VCAM1	2.57e-03	235	109	6	SM00408
Domain	Ig_sub2	PECAM1 SIGLEC14 SIGLEC5 LRRC4 KDR VCAM1	2.57e-03	235	109	6	IPR003598
Domain	DNAJ_1	DNAJC25 DNAJC28 SACS	2.93e-03	49	109	3	PS00636
Domain	DNAJ_2	DNAJC25 DNAJC28 SACS	2.93e-03	49	109	3	PS50076
Domain	DnaJ	DNAJC25 DNAJC28 SACS	2.93e-03	49	109	3	SM00271
Domain	-	DNAJC25 DNAJC28 SACS	2.93e-03	49	109	3	1.10.287.110
Domain	CARBOXYLESTERASE_B_2	NLGN4Y NLGN4X	2.93e-03	14	109	2	PS00941
Domain	COesterase	NLGN4Y NLGN4X	2.93e-03	14	109	2	PF00135
Domain	CarbesteraseB	NLGN4Y NLGN4X	2.93e-03	14	109	2	IPR002018
Domain	DnaJ_domain	DNAJC25 DNAJC28 SACS	3.29e-03	51	109	3	IPR001623
Domain	LRR_8	LRRC37A3 LRRC37A2 LRRIQ4 LRRC4 LRRC37A	3.30e-03	171	109	5	PF13855
Domain	Leu-rich_rpt_typical-subtyp	LRRC37A3 LRRC37A2 LRRIQ4 LRRC4 LRRC37A	3.82e-03	177	109	5	IPR003591
Domain	LRR_TYP	LRRC37A3 LRRC37A2 LRRIQ4 LRRC4 LRRC37A	3.82e-03	177	109	5	SM00369
Domain	Nucleotide-bd_a/b_plait	NMI RBM27 SYNJ2 RBM6 PARN EIF3G	4.06e-03	258	109	6	IPR012677
Domain	V-set	SIGLEC14 SIGLEC5 CD8B KDR VCAM1	4.50e-03	184	109	5	PF07686
Domain	PRAME_family	PRAMEF5 PRAMEF6	5.41e-03	19	109	2	IPR026271
Pubmed	The human cytoplasmic dynein interactome reveals novel activators of motility.	EDF1 IFT74 VPS13C STXBP4 KIAA0319L MLXIP STAT3 KIAA1671 NCOR1 BRCA2 SYNJ2 PRMT5 XRN1 EIF3G UBE3C FAM110B	3.82e-08	853	119	16	28718761
Pubmed	Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.	SF3A1 GARS1 EIF3E EVPL NOL10 PPL KIAA1671 CEP170 USP10 RBM27 ANLN PRMT5 ANGEL2 EIF3L MRPS9 EIF3G GNAS WDR1 MTREX	5.58e-08	1257	119	19	36526897
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	STRBP SF3A1 EIF3E NOL10 ANKHD1 TRRAP CEP170 AP1B1 PRMT5 EIF3L XRN1 RBM6 PARN MTREX	5.70e-08	653	119	14	22586326
Pubmed	Human transcription factor protein interaction networks.	STRBP EIF3E KLF3 ANKHD1 TRRAP STAT3 KIAA1671 NCOR1 BRCA1 RBM27 EIF3L XRN1 RBM6 MRPS9 TIMM29 EIF3G WDR1 PHF10 LRIF1 SORL1	8.36e-08	1429	119	20	35140242
Pubmed	Primate segmental duplication creates novel promoters for the LRRC37 gene family within the 17q21.31 inversion polymorphism region.	LRRC37A3 LRRC37A2 LRRC37A	1.56e-07	4	119	3	22419166
Pubmed	RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia.	STAT3 BRCA1 BRCA2	1.56e-07	4	119	3	32945515
Pubmed	Platelet-endothelial cell adhesion molecule-1 regulates endothelial NO synthase activity and localization through signal transducers and activators of transcription 3-dependent NOSTRIN expression.	PECAM1 STAT3 NOSTRIN	1.56e-07	4	119	3	21183735
Pubmed	Brachyury is required for elongation and vasculogenesis in the murine allantois.	PECAM1 KDR VCAM1	3.89e-07	5	119	3	16835439
Pubmed	Negative regulation of CD8 expression via Cd8 enhancer-mediated recruitment of the zinc finger protein MAZR.	NCOR1 CD8B CD8B2	7.75e-07	6	119	3	16491076
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	EDF1 EIF3E NOL10 ANKHD1 TRRAP AHDC1 KIAA1671 USP10 PPP2R5C BRCA1 RBM27 ANLN PRMT5 EIF3L XRN1 RBM6 PARN EIF3G MTREX	8.04e-07	1497	119	19	31527615
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	IFT74 STXBP4 ZDBF2 RABGAP1 KIAA1671 NCOR1 BRCA2 RBM6 GNAS MTREX LRIF1 SORL1	8.96e-07	588	119	12	38580884
Pubmed	The HIV-1 Tat protein recruits a ubiquitin ligase to reorganize the 7SK snRNP for transcriptional activation.	EDF1 STRBP SF3A1 DOCK9 GARS1 EIF3E USF3 AP1B1 RBM27 PRMT5 KRT222 EIF3L MRPS9 EIF3G MTREX PHF10	2.10e-06	1153	119	16	29845934
Pubmed	Systematic analysis of human protein complexes identifies chromosome segregation proteins.	SF3A1 STXBP4 GARS1 EIF3E PPL CEP170 PPP2R5C SYNJ2 ANLN PRMT5 EIF3L EIF3G GNAS COG5 PHF10 FAM110B	2.15e-06	1155	119	16	20360068
Pubmed	FoxO1 is required in endothelial but not myocardial cell lineages during cardiovascular development.	PECAM1 KDR VCAM1	2.16e-06	8	119	3	22411556
Pubmed	Differences in gene expression between mouse and human for dynamically regulated genes in early embryo.	PRAMEF5 NLRP7 PRAMEF26 PRAMEF6	2.50e-06	28	119	4	25089626
Pubmed	TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.	EIF3E TRRAP EIF3L EIF3G	2.50e-06	28	119	4	29653964
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	IFT74 ANKHD1 TRRAP STAT3 KIAA1671 CEP170 NCOR1 USP10 RBM27 ANLN XRN1	3.12e-06	549	119	11	38280479
Pubmed	A genome-wide in situ hybridization map of RNA-binding proteins reveals anatomically restricted expression in the developing mouse brain.	PRAMEF5 STRBP SF3A1 ANKHD1 RBM27 SYNJ2 RBM6 PRMT2 PRAMEF6	3.26e-06	347	119	9	16033648
Pubmed	HERC2 Facilitates BLM and WRN Helicase Complex Interaction with RPA to Suppress G-Quadruplex DNA.	EIF3E BRCA1 EIF3L EIF3G	3.82e-06	31	119	4	30279242
Pubmed	The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts.	EDF1 STRBP SF3A1 EIF3E NOL10 ANKHD1 USP10 RBM27 EIF3L XRN1 RBM6 MRPS9 EIF3G	4.19e-06	807	119	13	22681889
Pubmed	Proteome-wide identification of HSP70/HSC70 chaperone clients in human cells.	EDF1 IFT74 SF3A1 GARS1 EIF3E RABGAP1 XPNPEP1 PPL CEP170 ANKRD13A AP1B1 ANLN GPNMB EIF3G GNAS WDR1 COG5	4.27e-06	1367	119	17	32687490
Pubmed	Evolutionary dynamism of the primate LRRC37 gene family.	LRRC37A3 LRRC37A2 LRRC37A	4.61e-06	10	119	3	23064749
Pubmed	TRIM65 regulates microRNA activity by ubiquitination of TNRC6.	STRBP GARS1 EIF3E ANKHD1 TRRAP CEP170 ANGEL2 MTREX SORL1	4.80e-06	364	119	9	24778252
Pubmed	The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.	EDF1 STRBP SF3A1 NOL10 ZDBF2 CEP170 NCOR1 BRCA1 BRCA2 RBM27 ANLN EIF3L RBM6 PARN	5.10e-06	954	119	14	36373674
Pubmed	High-sensitivity profiling of SARS-CoV-2 noncoding region-host protein interactome reveals the potential regulatory role of negative-sense viral RNA.	STRBP SF3A1 GARS1 EIF3E PRMT5 EIF3L XRN1 MRPS9 EIF3G MTREX	5.19e-06	469	119	10	37314180
Pubmed	Nuclear control of lung cancer cells migration, invasion and bioenergetics by eukaryotic translation initiation factor 3F.	EIF3E STAT3 PRMT5 EIF3L EIF3G	6.14e-06	75	119	5	31527668
Pubmed	Retinoic acid receptors are required for skeletal growth, matrix homeostasis and growth plate function in postnatal mouse.	PRAMEF5 NCOR1 PRAMEF26 PRAMEF6	6.28e-06	35	119	4	19389355
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	IFT74 STXBP4 MLXIP STAT3 KIAA1671 CEP170 SYNJ2 ANLN PRMT5 XRN1 GNAS MTREX FAM110B	8.38e-06	861	119	13	36931259
Pubmed	The S52F FOXF1 Mutation Inhibits STAT3 Signaling and Causes Alveolar Capillary Dysplasia.	PECAM1 STAT3 KDR	8.40e-06	12	119	3	31199666
Pubmed	Reconstitution reveals the functional core of mammalian eIF3.	EIF3E EIF3L EIF3G	8.40e-06	12	119	3	17581632
Pubmed	MRG15 is a novel PALB2-interacting factor involved in homologous recombination.	TRRAP BRCA1 BRCA2	8.40e-06	12	119	3	19553677
Pubmed	eIF3 targets cell-proliferation messenger RNAs for translational activation or repression.	EIF3E EIF3L EIF3G	8.40e-06	12	119	3	25849773
Pubmed	Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice.	PECAM1 KDR VCAM1	8.40e-06	12	119	3	16895970
Pubmed	A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.	EDF1 STRBP EIF3E STAT3 KIAA1671 CEP170 ANKRD13A USP10 PRMT5 EIF3L MRPS9 EIF3G UBE3C GNAS WDR1 MTREX COG5	8.44e-06	1440	119	17	30833792
Pubmed	The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.	STRBP SF3A1 EIF3E ARMC10 CEP170 SACS ANLN TIMM29 MTREX	1.02e-05	400	119	9	35013556
Pubmed	Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular homeostasis.	PECAM1 GARS1 KDR	1.09e-05	13	119	3	28835631
Pubmed	eIF3: a versatile scaffold for translation initiation complexes.	EIF3E EIF3L EIF3G	1.09e-05	13	119	3	16920360
Pubmed	STAT5 is required for thymopoiesis in a development stage-specific manner.	CD8B CD8B2 VCAM1	1.09e-05	13	119	3	15294943
Pubmed	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.	STXBP4 GARS1 EIF3E NOL10 STAT3 CEP170 EIF3L MRPS9 TIMM29 EIF3G UBE3C MTREX	1.13e-05	754	119	12	33060197
Pubmed	Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.	BRCA1 BRCA2	1.16e-05	2	119	2	29480828
Pubmed	A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.	BRCA1 BRCA2	1.16e-05	2	119	2	17924331
Pubmed	Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.	BRCA1 BRCA2	1.16e-05	2	119	2	12833555
Pubmed	Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation.	BRCA1 BRCA2	1.16e-05	2	119	2	14735173
Pubmed	Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	16032702
Pubmed	Oral contraceptive use and BRCA penetrance: a case-only study.	BRCA1 BRCA2	1.16e-05	2	119	2	19549808
Pubmed	Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study.	BRCA1 BRCA2	1.16e-05	2	119	2	34101484
Pubmed	Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.	BRCA1 BRCA2	1.16e-05	2	119	2	26961146
Pubmed	Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study.	BRCA1 BRCA2	1.16e-05	2	119	2	20512419
Pubmed	Deleterious and ethnic-related BRCA1/2 mutations in tissue and blood of Egyptian colorectal cancer patients and its correlation with human papillomavirus.	BRCA1 BRCA2	1.16e-05	2	119	2	37804357
Pubmed	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.	BRCA1 BRCA2	1.16e-05	2	119	2	22053997
Pubmed	Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus.	SIGLEC14 SIGLEC5	1.16e-05	2	119	2	24799499
Pubmed	BRCA mutations in women with inflammatory breast cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	29044548
Pubmed	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.	BRCA1 BRCA2	1.16e-05	2	119	2	33834176
Pubmed	Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring.	BRCA1 BRCA2	1.16e-05	2	119	2	18200524
Pubmed	Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.	BRCA1 BRCA2	1.16e-05	2	119	2	29298688
Pubmed	Fertility in women with BRCA mutations: a case-control study.	BRCA1 BRCA2	1.16e-05	2	119	2	19200971
Pubmed	Prevalence of BRCA mutations and founder effect in high-risk Hispanic families.	BRCA1 BRCA2	1.16e-05	2	119	2	16030099
Pubmed	Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.	BRCA1 BRCA2	1.16e-05	2	119	2	28212807
Pubmed	Genetic counseling impacts decision for prophylactic surgery for patients perceived to be at high risk for breast cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	11448436
Pubmed	Rapid evolution of BRCA1 and BRCA2 in humans and other primates.	BRCA1 BRCA2	1.16e-05	2	119	2	25011685
Pubmed	Breast magnetic resonance imaging for screening high-risk women.	BRCA1 BRCA2	1.16e-05	2	119	2	23928241
Pubmed	Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	35980168
Pubmed	Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.	BRCA1 BRCA2	1.16e-05	2	119	2	11377596
Pubmed	BRCA mutations and risk of prostate cancer in Ashkenazi Jews.	BRCA1 BRCA2	1.16e-05	2	119	2	15131025
Pubmed	Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population.	BRCA1 BRCA2	1.16e-05	2	119	2	20033483
Pubmed	Health survey and assessment of the polymorphisms BRCA1/P871L, BRCA1/Q356R, and BRCA2/N372H in female gas station workers in Rio de Janeiro.	BRCA1 BRCA2	1.16e-05	2	119	2	28862356
Pubmed	BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.	BRCA1 BRCA2	1.16e-05	2	119	2	22425665
Pubmed	BRCA1/2 in high-risk African American women with breast cancer: providing genetic testing through various recruitment strategies.	BRCA1 BRCA2	1.16e-05	2	119	2	18752448
Pubmed	Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.	BRCA1 BRCA2	1.16e-05	2	119	2	22425664
Pubmed	Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.	BRCA1 BRCA2	1.16e-05	2	119	2	22970155
Pubmed	Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study.	BRCA1 BRCA2	1.16e-05	2	119	2	34304065
Pubmed	Absence of 185delAG and 6174delT Mutations among Breast Cancer Patients of Eastern India.	BRCA1 BRCA2	1.16e-05	2	119	2	26625823
Pubmed	Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	26852015
Pubmed	Meta-analysis of BRCA1 and BRCA2 penetrance.	BRCA1 BRCA2	1.16e-05	2	119	2	17416853
Pubmed	Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment.	BRCA1 BRCA2	1.16e-05	2	119	2	18175183
Pubmed	Presence of crown-like structures in breast adipose tissue; differences between healthy controls, BRCA1/2 gene mutation carriers and breast cancer patients.	BRCA1 BRCA2	1.16e-05	2	119	2	38057686
Pubmed	Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.	BRCA1 BRCA2	1.16e-05	2	119	2	27914478
Pubmed	BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.	BRCA1 BRCA2	1.16e-05	2	119	2	16455195
Pubmed	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.	BRCA1 BRCA2	1.16e-05	2	119	2	23810788
Pubmed	Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.	BRCA1 BRCA2	1.16e-05	2	119	2	29727326
Pubmed	Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study.	BRCA1 BRCA2	1.16e-05	2	119	2	35871032
Pubmed	Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry.	BRCA1 BRCA2	1.16e-05	2	119	2	22739995
Pubmed	The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.	BRCA1 BRCA2	1.16e-05	2	119	2	27794048
Pubmed	Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution.	BRCA1 BRCA2	1.16e-05	2	119	2	20972632
Pubmed	BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients.	BRCA1 BRCA2	1.16e-05	2	119	2	19499246
Pubmed	Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation.	BRCA1 BRCA2	1.16e-05	2	119	2	19656164
Pubmed	Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	15986445
Pubmed	Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	18165636
Pubmed	Large genomic rearrangements in BRCA1 and BRCA2: implications for patient care.	BRCA1 BRCA2	1.16e-05	2	119	2	23615136
Pubmed	Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.	BRCA1 BRCA2	1.16e-05	2	119	2	29982601
Pubmed	Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	28343309
Pubmed	BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.	BRCA1 BRCA2	1.16e-05	2	119	2	17925560
Pubmed	Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.	BRCA1 BRCA2	1.16e-05	2	119	2	27601588
Pubmed	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	23918944
Pubmed	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.	BRCA1 BRCA2	1.16e-05	2	119	2	33558422
Pubmed	Breast cancer risk associated with BRCA1/2 variants in the Pakistani population.	BRCA1 BRCA2	1.16e-05	2	119	2	30430339
Pubmed	Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.	BRCA1 BRCA2	1.16e-05	2	119	2	33534430
Pubmed	BRCA 1, 2 mutation and earlier menopause: could BRCA 1,2 be used as predictor of menopause?	BRCA1 BRCA2	1.16e-05	2	119	2	34137566
Pubmed	BRCA1/2 Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing.	BRCA1 BRCA2	1.16e-05	2	119	2	33918338
Pubmed	Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.	BRCA1 BRCA2	1.16e-05	2	119	2	26181175
Interaction	HOXC12 interactions	XPNPEP1 JADE1 BRCA1 SORL1	8.36e-07	14	111	4	int:HOXC12
Interaction	KDM1A interactions	IFT74 KLF3 ZDBF2 RABGAP1 ANKHD1 TRRAP STAT3 ESCO2 KIAA1671 NCOR1 NMI BRCA1 BRCA2 PRMT5 KRT222 XRN1 UBE3C NOSTRIN CCDC33	8.63e-07	941	111	19	int:KDM1A
Interaction	WWTR1 interactions	IFT74 ANKHD1 TRRAP STAT3 KIAA1671 CEP170 NCOR1 USP10 RBM27 ANLN XRN1	2.16e-05	422	111	11	int:WWTR1
Interaction	RPL5 interactions	EDF1 NLRP7 DNAJC25 EIF3E USP10 BRCA1 ANLN PRMT5 EIF3L XRN1 EIF3G MTREX VCAM1	2.92e-05	606	111	13	int:RPL5
Interaction	CSNK2A3 interactions	SF3A1 EIF3E CEP170 EIF3L PARN EIF3G	3.28e-05	110	111	6	int:CSNK2A3
Interaction	RPA4 interactions	IFT74 SF3A1 KIAA0319L ANKHD1 TRRAP KIAA1671 CEP170 NCOR1 BRCA1 RBM27 EIF3G	4.04e-05	452	111	11	int:RPA4
Cytoband	17p11.2	CCDC144CP NCOR1 MEIS3P2 CCDC144NL CCDC144A	5.97e-05	159	118	5	17p11.2
Cytoband	Ensembl 112 genes in cytogenetic band chr17p11	CCDC144CP NCOR1 MEIS3P2 CCDC144NL CCDC144A	1.88e-04	203	118	5	chr17p11
Cytoband	7p15	GARS1 GPNMB	5.84e-04	14	118	2	7p15
Cytoband	1p36.21	PRAMEF5 PRAMEF26 PRAMEF6	5.87e-04	63	118	3	1p36.21
Cytoband	2q12.1	CD8B2 MRPS9	1.09e-03	19	118	2	2q12.1
Cytoband	17q21.31	LRRC37A2 STAT3 LRRC37A	1.26e-03	82	118	3	17q21.31
GeneFamily	Eukaryotic translation initiation factor 3	EIF3E EIF3L EIF3G	1.83e-05	13	74	3	1121
GeneFamily	PRAME family	PRAMEF5 PRAMEF26 PRAMEF6	1.25e-04	24	74	3	686
GeneFamily	EF-hand domain containing\|Plakins	EVPL PPL	4.55e-04	8	74	2	939
GeneFamily	Protein arginine methyltransferases	PRMT5 PRMT2	5.84e-04	9	74	2	691
GeneFamily	DNAJ (HSP40) heat shock proteins\|C2 tensin-type domain containing	DNAJC25 DNAJC28 SACS	1.06e-03	49	74	3	584
GeneFamily	Ring finger proteins\|Fanconi anemia complementation groups\|Protein phosphatase 1 regulatory subunits\|BRCA1 A complex\|BRCA1 B complex\|BRCA1 C complex	BRCA1 BRCA2	2.99e-03	20	74	2	548
GeneFamily	Olfactory receptors, family 9	OR9A1P OR9A2	3.95e-03	23	74	2	156
GeneFamily	Adenosine receptors\|V-set domain containing	SIGLEC14 SIGLEC5 CD8B KDR	4.49e-03	163	74	4	590
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	PECAM1 SIGLEC5 IFNGR1 CD8B KDR VCAM1	5.49e-03	394	74	6	471
GeneFamily	CD molecules\|C2-set domain containing\|Sialic acid binding Ig like lectins	SIGLEC14 SIGLEC5	5.83e-03	28	74	2	745
GeneFamily	Armadillo repeat containing\|Protein phosphatase 1 regulatory subunits	NCOR1 BRCA1 SACS SH3RF2	6.48e-03	181	74	4	694
Coexpression	HAMAI_APOPTOSIS_VIA_TRAIL_UP	OMA1 IFT74 STRBP VPS13C EIF3E ANKHD1 LRRC4 CEP170 NMI BRCA1 SACS RBM27 ANLN MTREX SORL1	1.71e-07	656	114	15	M18979
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	DOCK9 RABGAP1 TRRAP AHDC1 TSPAN5 CEP170 PPP2R5C ELL2 BRCA1 BRCA2 SACS SYNJ2 RBM6 PARN MTREX COG5	9.47e-07	856	114	16	M4500
Coexpression	GSE5099_UNSTIM_VS_MCSF_TREATED_MONOCYTE_DAY7_UP	STRBP EIF3E JADE1 ANKHD1 PPP2R5C EIF3L PHF10 LRIF1	2.75e-06	200	114	8	M6584
Coexpression	GSE8621_LPS_PRIMED_UNSTIM_VS_LPS_PRIMED_AND_LPS_STIM_MACROPHAGE_DN	ESCO2 BRCA1 SACS SYNJ2 PLCB1 MRPS9 LRIF1 SORL1	2.75e-06	200	114	8	M6975
Coexpression	GSE10147_IL3_VS_IL3_AND_HIVP17_STIM_PDC_UP	IFT74 VPS13C KIAA0319L MLXIP ANGEL2 UBE3C SORL1	8.39e-06	166	114	7	M344
Coexpression	RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN	C8orf88 STRBP VPS13C LRRC37A2 MLXIP TSPAN5 KIAA1671 NCOR1 ELL2 SYNJ2 PRMT2 ENPP5 GNAS SORL1	1.11e-05	807	114	14	M16651
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	VPS13C SF3A1 DOCK9 PECAM1 JADE1 TSPAN5 STAT3 NCOR1 PPP2R5C CD8B SACS RBM27 XRN1 OXNAD1 PRMT2 GNAS WDR1 PIK3R5 SORL1	2.28e-05	1492	114	19	M40023
Coexpression	GEORGES_TARGETS_OF_MIR192_AND_MIR215	VPS13C STXBP4 JADE1 CHM ESCO2 ANKRD13A NMI ELL2 BRCA1 BRCA2 ANLN PARN GNAS PHF10	3.37e-05	892	114	14	M18120
Coexpression	YAMAZAKI_TCEB3_TARGETS_DN	PRAMEF5 STRBP JADE1 ESCO2 PRAMEF26 PRAMEF6 SORL1	7.17e-05	232	114	7	MM1019
ToppCell	lymphoid-T_cell-CD8+_Naive_T_cell\|lymphoid / Lineage, cell class and subclass	PECAM1 EIF3E CD8B EIF3L OXNAD1 PRMT2 EIF3G WDR1	5.37e-08	199	116	8	22926327c93ede9f3408c99a0d56e373a33240ef
ToppCell	Children_(3_yrs)-Endothelial-capillary_endothelial_cell_(Cap1)-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DOCK9 PECAM1 KIAA1671 PCDH15 PLCB1 KDR NOSTRIN	6.32e-07	188	116	7	117dc80fa940e6aa1b0187a43fdde33f3fcb578f
ToppCell	Severe-CD8+_T\|World / Disease group and Cell class	PECAM1 CD8B PLCB1 ENPP5 VCAM1	7.05e-07	64	116	5	3e7ede6ec5d8b9c4fc6f3aa8fda91fd9b763ef18
ToppCell	RV-10._Endothelium_II\|World / Chamber and Cluster_Paper	DOCK9 PECAM1 TSPAN5 KIAA1671 PCDH15 NOSTRIN VCAM1	7.53e-07	193	116	7	2531266bc57339d4e2b22a88817008e32b8c1598
ToppCell	COVID-19_Mild-CD8+_T_naive\|COVID-19_Mild / Disease condition and Cell class	PECAM1 EIF3E MLXIP CD8B CD8B2 OXNAD1 PRMT2	7.80e-07	194	116	7	4e42df4f6db456ab914ddfb2a938dfc462f8b6bf
ToppCell	Fetal_29-31_weeks-Endothelial-endothelial_cell_of_vein\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN VCAM1	7.80e-07	194	116	7	fc2e0081005c0c496e41197a2d06e4a37708221f
ToppCell	(2)_NK/T-(221)_CD8+_Naive_T_cell\|(2)_NK/T / immune cells in Peripheral Blood (logTPM normalization)	PECAM1 EIF3E MLXIP CD8B CD8B2 OXNAD1 PRMT2	8.64e-07	197	116	7	5943f30288d4c9a7d7ef2e85461487a229f44511
ToppCell	Severe-CD8+_T\|Severe / Disease group and Cell class	PECAM1 CD8B PLCB1 ENPP5 VCAM1	4.53e-06	93	116	5	433d23253b2102cf65df338a488554e5ab409d7e
ToppCell	Control-Endothelial_cells-Systemic_venous_endothelial_cells\|Control / group, cell type (main and fine annotations)	DOCK9 PECAM1 PLCB1 KDR NOSTRIN TMPRSS11A	5.99e-06	172	116	6	c55dce1ed3ed7312394b4e050e1de852a994e130
ToppCell	COVID-19_Convalescent-Lymphoid_T/NK-CD8+_T_naive\|COVID-19_Convalescent / Disease group, lineage and cell class	EIF3E MLXIP CD8B CD8B2 OXNAD1 PRMT2	8.81e-06	184	116	6	0299cd30a3ea8e861a9d529043c204048ae21d29
ToppCell	PBMC-Convalescent-Lymphocyte-T/NK-CD8+_T-CD8+_T_naive\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	EIF3E MLXIP CD8B CD8B2 OXNAD1 PRMT2	9.09e-06	185	116	6	27dbfcd40ec832d5cf757331d8af3b5176ae90fb
ToppCell	PBMC-Convalescent-Lymphocyte-T/NK-CD8+_T-CD8+_T_naive-\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	EIF3E MLXIP CD8B CD8B2 OXNAD1 PRMT2	9.09e-06	185	116	6	ca8e921a6b45cd39474b9f86c95e7be023585c5d
ToppCell	3'-GW_trimst-2-LargeIntestine-Endothelial-blood_vessel_EC-Fetal_arterial_EC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DOCK9 PECAM1 KIAA1671 SYNJ2 PLCB1 KDR	9.66e-06	187	116	6	25efb82afe863a853ecdd781ad89026c993aaa67
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	DOCK9 PPP2R5C CD8B OXNAD1 PRMT2 SORL1	1.03e-05	189	116	6	9ab77c6fcb573854da5922412f53d2168bda6b58
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	DOCK9 PPP2R5C CD8B OXNAD1 PRMT2 SORL1	1.03e-05	189	116	6	5a9e2ca9a9ee2dc37ab9147a902115a9f1a80169
ToppCell	Control-Endothelial-Endothelial-Alv_Gen_Intermediate\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DOCK9 PECAM1 TSPAN5 KIAA1671 KDR NOSTRIN	1.03e-05	189	116	6	5d7ae1ead7f4fbaeec26f651833c9c2106e1e4d1
ToppCell	COVID-19-Endothelial_cells-Endothelial_cells_(general)\|COVID-19 / group, cell type (main and fine annotations)	DOCK9 PECAM1 NLGN4X PLCB1 KDR NOSTRIN	1.06e-05	190	116	6	812e11314c76c0179fbe5a9bea29b41ce5cbc93d
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Cycling_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK9 PECAM1 ESCO2 BRCA1 BRCA2 ANLN	1.06e-05	190	116	6	31de1727822e9818652946dfb962daee77ffad68
ToppCell	COVID-19-Heart-EC_3\|Heart / Disease (COVID-19 only), tissue and cell type	DOCK9 PECAM1 KIAA1671 PLCB1 NOSTRIN VCAM1	1.06e-05	190	116	6	78e7c502b0450c0b37652b1896a2a752fd8a2111
ToppCell	RA-09._Endothelium_I\|World / Chamber and Cluster_Paper	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	1.09e-05	191	116	6	c8a0c2af119bc34a8f694a7d30642f28002c84b9
ToppCell	COVID-19-Heart-EC_(POSTN)\|Heart / Disease (COVID-19 only), tissue and cell type	DOCK9 PECAM1 TSPAN5 PCDH15 NOSTRIN VCAM1	1.12e-05	192	116	6	c0c34785a7bdf461722029b322e9184e3d9b3c26
ToppCell	COVID-19-kidney-AQP1+PLVAP+EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	1.12e-05	192	116	6	27ff3621e177e7932dd44dd6baa81551ea75a874
ToppCell	LPS-IL1RA+antiTNF-Endothelial-Endothelial-Gen_Cap\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	1.16e-05	193	116	6	e09387af84d2a0a526e54d4793e6e06c6739db53
ToppCell	LPS-antiTNF-Endothelial-Endothelial-Gen_Cap\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	1.16e-05	193	116	6	6e1982d089a9de628e6006d23ff78a223fbd9f47
ToppCell	Control-Endothelial-Endothelial\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DOCK9 PECAM1 TSPAN5 KIAA1671 KDR NOSTRIN	1.16e-05	193	116	6	aff0649c73c634bc6ff0dc7759b4693a9236bf05
ToppCell	Control-CD8+_T_naive\|Control / Disease condition and Cell class	PECAM1 EIF3E MLXIP CD8B CD8B2 OXNAD1	1.16e-05	193	116	6	627d345baf1940218c61907305705298e473dbab
ToppCell	LPS_only-Endothelial-Endothelial-Gen_Cap\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	1.16e-05	193	116	6	af5108260783e69a7d67896c5bf64f862525926d
ToppCell	Control-Endothelial\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DOCK9 PECAM1 TSPAN5 KIAA1671 KDR NOSTRIN	1.16e-05	193	116	6	c5f9fe03e64c211d4bcd4959e5b32f14841e336a
ToppCell	Fetal_29-31_weeks-Endothelial-capillary_endothelial_cell_(Cap1)-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	DOCK9 PECAM1 KIAA1671 NLGN4X KDR NOSTRIN	1.16e-05	193	116	6	ff6e6b825d6c88148216c601580be3c28851ab5c
ToppCell	RV-09._Endothelium_I\|World / Chamber and Cluster_Paper	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	1.16e-05	193	116	6	e3fa47e2c7cd8a5b69186711c57751f2296de8ae
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	1.19e-05	194	116	6	0b9cd96fa0b616da7cc90e92ff71157e9bba518f
ToppCell	LA-09._Endothelium_I\|World / Chamber and Cluster_Paper	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	1.23e-05	195	116	6	fc95457a298b5d0dab687d9ee7e225a7f7b9a0d4
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Peritubular_Capilary_Endothelial_Cell_\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK9 PECAM1 PLCB1 KDR NOSTRIN VCAM1	1.23e-05	195	116	6	818bc18c5834238e5f733cac6fe928ed0788f57d
ToppCell	LV-09._Endothelium_I\|World / Chamber and Cluster_Paper	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	1.23e-05	195	116	6	19e0a6c3eae1615aaa39767300acd937dfcb2a7f
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK9 PECAM1 PLCB1 KDR NOSTRIN VCAM1	1.26e-05	196	116	6	7cbb19108b4553ef60ef5c230a29de1662c02efe
ToppCell	ILEUM-inflamed-(1)_Naive_T_cells\|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	EIF3E KLF3 STAT3 OXNAD1 PRMT2 SORL1	1.26e-05	196	116	6	72a34b81663475ab378b3bb9a02136df286881b3
ToppCell	severe_influenza-CD8+_Tem\|World / disease group, cell group and cell class (v2)	TSPAN5 KIAA1671 PPP2R5C CD8B CD8B2 ENPP5	1.26e-05	196	116	6	40fb254abcab2e65affc5d6037e71893a031d264
ToppCell	COVID-19-lung-Capillary_1\|lung / Disease (COVID-19 only), tissue and cell type	DOCK9 PECAM1 NLGN4X PCDH15 KDR NOSTRIN	1.30e-05	197	116	6	7e86ff9dafcbaaa7464d61484dd48bfeb7eae6e4
ToppCell	(221)_CD8+_Naive_T_cell\|World / immune cells in Peripheral Blood (logTPM normalization)	EIF3E MLXIP CD8B CD8B2 OXNAD1 PRMT2	1.30e-05	197	116	6	59621a1f016b9f467e69bd5977ccdafa03b4ce21
ToppCell	(2)_NK/T-(22)_CD8+_T_cell\|(2)_NK/T / immune cells in Peripheral Blood (logTPM normalization)	PECAM1 IFNGR1 PPP2R5C CD8B CD8B2 PLCB1	1.30e-05	197	116	6	20dad8e4ed36a0185e231ddcb327725d2b2005e0
ToppCell	LV-09._Endothelium_I\|LV / Chamber and Cluster_Paper	DOCK9 PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	1.30e-05	197	116	6	f9731d4d636e51b94a96805eee6afe9aedc175e3
ToppCell	Parenchymal-NucSeq-Endothelial-Endothelia_vascular-VE_capillary\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	PECAM1 NLGN4X PCDH15 PLCB1 KDR NOSTRIN	1.34e-05	198	116	6	1d30a1f73b6d6d838f49751402a29c5ef54aa81f
ToppCell	10x5'-lymph-node_spleen-Lymphocytic_T_CD8-Tnaive/CM_CD8\|lymph-node_spleen / Manually curated celltypes from each tissue	PECAM1 EIF3E CD8B CD8B2 OXNAD1 PRMT2	1.34e-05	198	116	6	e9762695a2a23ade8888f9d98b5d259c7f1685f7
ToppCell	Caecum-T_cell-Activated_CD4_T\|T_cell / Region, Cell class and subclass	EIF3E KLF3 STAT3 CEP170 USP10 SORL1	1.38e-05	199	116	6	13173cc4dcc8e856680372b0a4ad4f36afa892c1
ToppCell	lymphoid-T_cell-CD8+_Naive_T_cell\|World / Lineage, cell class and subclass	EIF3E CD8B EIF3L OXNAD1 PRMT2 EIF3G	1.38e-05	199	116	6	4de81f29c4d79868fd6254ceb81b4ddad22ae7d0
ToppCell	Bronchial-NucSeq-Immune_Lymphocytic-T-T_CD8\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	TSPAN5 PPP2R5C CD8B PLCB1 OXNAD1 PIK3R5	1.41e-05	200	116	6	02c4169a23e5aaa0d4bfc78b51ba19ce8157dc3e
ToppCell	COVID-19-kidney-Mito-rich_EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PECAM1 LRRIQ4 PLCB1 KDR NOSTRIN	3.90e-05	145	116	5	afed661aef990edb8e7012ab67ace56443520c9f
ToppCell	ICU-SEP-Lymphocyte-T_NK-CD8_Naive\|ICU-SEP / Disease, Lineage and Cell Type	EVPL KIAA1671 CD8B DNAJC28 OXNAD1	4.44e-05	149	116	5	a66f3ebf6214b269b137ddd5f4d8d7fb3ef2d962
ToppCell	PND07-Endothelial-Endothelial_lymphatic\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	C8orf88 DOCK9 KIAA1671 KDR GNAS	6.42e-05	161	116	5	133b4fadb499e842c19f573f9cf09ce08c1d4813
ToppCell	PND07-Endothelial-Endothelial_lymphatic-Lymphatic_EC\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	C8orf88 DOCK9 KIAA1671 KDR GNAS	6.42e-05	161	116	5	9466b8658244116f8d21f2f88fb8c2d184b1bdf2
ToppCell	PND07-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	C8orf88 DOCK9 KIAA1671 KDR GNAS	6.42e-05	161	116	5	cb177ca10d848d0e25399ab5ebfcde1071fb94c2
ToppCell	PND07-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	C8orf88 DOCK9 KIAA1671 KDR GNAS	6.61e-05	162	116	5	96c6e94a10b124a1d25dcd705ec5aaa8609c1089
ToppCell	Endothelial-endothelial_cell_of_bronchial_vessel\|World / Lineage, Cell type, age group and donor	PECAM1 KIAA1671 PLCB1 KDR NOSTRIN	7.21e-05	165	116	5	84e553d699ac56df89a77248f7308b9133e1b683
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Colon_Adenocarcinoma-4\|TCGA-Colorectal / Sample_Type by Project: Shred V9	GARS1 NOL10 BRCA1 RBM6 MRPS9	7.42e-05	166	116	5	52293b8a74d46e6161fb6a2e7e86e51fd9e89a5b
ToppCell	Fetal_29-31_weeks-Endothelial-endothelial_cell_of_vein-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	DOCK9 PECAM1 PLCB1 NOSTRIN VCAM1	7.42e-05	166	116	5	f7926ee266dcbf10df375cd921f1db5a2fa604f8
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Excitatory_Neuron.Gad1Gad2.Sgol2a_(Very_small_cluster)\|Striatum / BrainAtlas - Mouse McCarroll V32	EDF1 NOL10 PARN COG5 TMPRSS11A	8.07e-05	169	116	5	c3bf0cb67f200d02d5a021754e9b2a68d23ea168
ToppCell	3'-Broncho-tracheal-Endothelial-Blood_vessel_EC-capillary_endothelial_cell-EC_general_capillary-EC_general_capillary_L.2.0.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PECAM1 KRT222 PLCB1 KDR NOSTRIN	8.07e-05	169	116	5	0d8b681404e18f3061d84425fb5f7d84e8e2b8d7
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Excitatory_Neuron.Gad1Gad2.Sgol2a_(Very_small_cluster)--\|Striatum / BrainAtlas - Mouse McCarroll V32	EDF1 NOL10 PARN COG5 TMPRSS11A	8.07e-05	169	116	5	5375eb52ebadccb7bfff997a11985f23e81014d6
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Excitatory_Neuron.Gad1Gad2.Sgol2a_(Very_small_cluster)-\|Striatum / BrainAtlas - Mouse McCarroll V32	EDF1 NOL10 PARN COG5 TMPRSS11A	8.07e-05	169	116	5	1c132d21255f5a5174ac38db4e91927f9093418e
ToppCell	systemic_lupus_erythematosus-treated-Hematopoietic\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	EIF3E LRRIQ4 NLGN4X OXNAD1 PRMT2	8.30e-05	170	116	5	9a18756e6721980d4b6c37bb52ddfe93ca79c5ab
ToppCell	systemic_lupus_erythematosus-treated-Hematopoietic-Progen-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	EIF3E LRRIQ4 NLGN4X OXNAD1 PRMT2	8.53e-05	171	116	5	61d622153b91702ef21b0efc7b9581e592b7ccea
ToppCell	systemic_lupus_erythematosus-treated-Hematopoietic-Progen\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	EIF3E LRRIQ4 NLGN4X OXNAD1 PRMT2	8.53e-05	171	116	5	09b3fa120f63c411f8a0dd6bd230a9720ce83fb1
ToppCell	droplet-Trachea-3m-Hematologic-myeloid-granulocyte-\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SIGLEC5 ESCO2 BRCA1 ANLN PIK3R5	8.53e-05	171	116	5	41932c9e70829ee3d55ca5fdb74d290fc8229416
ToppCell	droplet-Liver-LIVER_HEP-30m-Lymphocytic\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZDBF2 CD8B XIRP2 SH3RF2 MEGF11	9.26e-05	174	116	5	ecdff386d7f0bc57c170a2c1f4deae5ba7e431b5
ToppCell	5'-GW_trimst-2-LymphNode-Endothelial-blood_vessel_EC-Fetal_venous_EC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NLGN4Y DOCK9 PECAM1 KDR NOSTRIN	9.26e-05	174	116	5	6b5ff1cc5fe6705f7ea70b5a892dfbf91e32288d
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	EIF3E STAT3 CD8B OXNAD1 EIF3G	9.51e-05	175	116	5	f456d8d958b71f7a942b718605712593d9de1bfd
ToppCell	Adult-Endothelial-endothelial_cell_of_vein\|Adult / Lineage, Cell type, age group and donor	PECAM1 PTHLH PLCB1 NOSTRIN VCAM1	9.77e-05	176	116	5	043683c61c5d1a7f8a4666a612310246bd3d83a2
ToppCell	3'-Broncho-tracheal-Endothelial-Blood_vessel_EC-capillary_endothelial_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PECAM1 KRT222 PLCB1 KDR NOSTRIN	1.00e-04	177	116	5	fdf2af00fc971f0cd3915e1416e4a256458d6ea8
ToppCell	3'-Broncho-tracheal-Endothelial-Blood_vessel_EC-capillary_endothelial_cell-EC_general_capillary\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PECAM1 KRT222 PLCB1 KDR NOSTRIN	1.00e-04	177	116	5	12f8627124acbf436e75681ff1ce429ff5e3f256
ToppCell	droplet-Liver-LIVER_HEP-30m-Lymphocytic-B_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZDBF2 XIRP2 SH3RF2 PCDH15 MEGF11	1.03e-04	178	116	5	d3cbdec9d75f076e565baca05ede292cca7758a4
ToppCell	PCW_13-14-Endothelial-Endothelial_mature-endo_arterial_(9)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	DOCK9 PECAM1 KIAA1671 NLGN4X KDR	1.03e-04	178	116	5	c227da59dc7beb73f84405bf13356bdeb59d9338
ToppCell	5'-Adult-LargeIntestine-Endothelial-lymphatic_endothelial-LEC5_(CLDN11+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	C8orf88 DOCK9 LRRC4 TSPAN5 FAM110B	1.06e-04	179	116	5	40c65e8623547aeb80f9cd2366e29072467ce069
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_B-plasmablast-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	NLRP7 ESCO2 BRCA2 ANLN CCDC144A	1.06e-04	179	116	5	021d782134126c6f7dce6b6ea50cc54bdaa39987
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_INF-A\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MLXIP NMI DNAJC28 BRCA2 PIK3R5	1.06e-04	179	116	5	06d412fc096d88de168969466ce422f0ab5553b2
ToppCell	droplet-Liver-LIVER_HEP-30m-Lymphocytic-B_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZDBF2 XIRP2 SH3RF2 PCDH15 MEGF11	1.06e-04	179	116	5	4135f9e8cd8494cbc189e5210dded84659643fb8
ToppCell	T_cells-GZMK+_CD8+_T_cells\|T_cells / Immune cells in Kidney/Urine in Lupus Nephritis	NLGN4Y STRBP KIAA1671 CD8B VCAM1	1.06e-04	179	116	5	798f208014f2229c597934775646ddbbacf94b69
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Endothelial-blood_vessel_EC-venous_capillary\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DOCK9 PECAM1 PLCB1 KDR NOSTRIN	1.09e-04	180	116	5	97e0dcb7cfbba60a782824c5e23995058609fcd4
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c06-NR4A2\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	DOCK9 STAT3 PPP2R5C OXNAD1 SORL1	1.09e-04	180	116	5	f3d35b2ea78afef37a84232adf5e6e26712b618d
ToppCell	COVID-19-Endothelial_cells-Endothelial_cells_(other)\|COVID-19 / group, cell type (main and fine annotations)	DOCK9 PECAM1 PLCB1 KDR NOSTRIN	1.11e-04	181	116	5	26eb4ee57a70dbf54e096b73129fda9dfda1f6ec
ToppCell	Endothelial-B-IPF_02\|World / lung cells shred on cell class, cell subclass, sample id	OVOS2 PM20D1 TSPAN5 CD8B KDR	1.11e-04	181	116	5	4fe0215d08f03d4e24749d70fce01b7aa22906fd
ToppCell	Severe-Lymphoid-T-innate_T\|Severe / Condition, Lineage, Cell class and cell subclass	DOCK9 PPP2R5C CD8B OXNAD1 VCAM1	1.11e-04	181	116	5	50ab8562552339d97e4f19aa6ae49fd797da492e
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Endothelial-blood_vessel_EC-cycling_EC\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PECAM1 LRRC4 BRCA2 KDR NOSTRIN	1.11e-04	181	116	5	4a225d9a6d113396c6b1d0a839bb4ca9c339a260
ToppCell	E16.5-samps-Endothelial-Immature_fetal_endothelial-Intermediate_Endothelial\|E16.5-samps / Age Group, Lineage, Cell class and subclass	DOCK9 PECAM1 KIAA1671 KDR NOSTRIN	1.14e-04	182	116	5	fec1caf867b1dc87b24504d895ee1a27df78062e
ToppCell	facs-Skin-Telogen-3m-Epithelial-epidermal_cell\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EVPL TSPAN5 PPL IFNGR1 AP1B1	1.17e-04	183	116	5	ed1e0b07475f9951728682ed70b85367cf2a744d
ToppCell	10x5'-bone_marrow-Lymphocytic_T_CD4/8-lo-Cycling_T\|bone_marrow / Manually curated celltypes from each tissue	ESCO2 CD8B CD8B2 BRCA1 BRCA2	1.17e-04	183	116	5	a48a6313f2f144586951cece97ec31f6d72361df
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3-Exc_L2-3_LINC00507_RPL9P17\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	COL24A1 SYNJ2 SH3RF2 CCDC144NL CCDC144A	1.17e-04	183	116	5	1645d4a55cd8c22d6eb47fc5c6b1e576c454f111
ToppCell	droplet-Lung-18m-Hematologic-myeloid-alveolar_macrophage-proliferating_alveolar_macrophage\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PM20D1 SIGLEC5 ESCO2 ANLN GPNMB	1.17e-04	183	116	5	e91f00b75d43ee6293fdd4a129b789cd95f8d11a
ToppCell	Control-Endothelial-Endothelial-Activated_Alv_Cap\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DOCK9 PECAM1 TSPAN5 KIAA1671 KDR	1.17e-04	183	116	5	e81c142770f44fd902b0631bc360c5b5339d4c75
ToppCell	3'-GW_trimst-2-SmallIntestine-Endothelial-blood_vessel_EC-cycling_EC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PECAM1 ESCO2 BRCA1 KDR NOSTRIN	1.20e-04	184	116	5	fa38d6a8709f520a027ad7e3ff783c84187ec467
ToppCell	3'-Child09-12-SmallIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DOCK9 PECAM1 PLCB1 KDR NOSTRIN	1.20e-04	184	116	5	842473fa415575441b595073a994b6d621169776
ToppCell	Dividing_Macrophages-IPF_01\|World / lung cells shred on cell class, cell subclass, sample id	C8orf88 ESCO2 BRCA1 BRCA2 ANLN	1.20e-04	184	116	5	f15ce786d25c6546804a6d1efcc2ad645f2ef54e
ToppCell	Control-Neu_4\|World / 5 Neutrophil clusters in COVID-19 patients	OMA1 RABGAP1 XPNPEP1 MLXIP ANLN	1.20e-04	184	116	5	ce7f044956613118ee2e9fb6af2455c3166cb414
ToppCell	remission-CD8+_T_naive\|remission / disease stage, cell group and cell class	EIF3E CD8B CD8B2 OXNAD1 PRMT2	1.20e-04	184	116	5	fe20fa4457d4a4a75689978275b0afb5f6243faf
ToppCell	PBMC-Convalescent-Lymphocyte-T/NK-CD8+_T-CD8+_T_naive\|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09)	EIF3E CD8B CD8B2 OXNAD1 PRMT2	1.23e-04	185	116	5	863a3d44c1f115942d7a2a2b63a92fe5fc768814
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	DOCK9 CD8B CD8B2 OXNAD1 PRMT2	1.23e-04	185	116	5	847257d232b9993cad50c814fd4ffeef52385295
ToppCell	remission-CD8+_T_naive\|World / disease stage, cell group and cell class	EIF3E CD8B CD8B2 OXNAD1 PRMT2	1.23e-04	185	116	5	69304d7dd406ac7e96d51c239d7035a06d88704f
ToppCell	COVID-19-Endothelial_cells-Systemic_venous_endothelial_cells\|COVID-19 / group, cell type (main and fine annotations)	DOCK9 PECAM1 PLCB1 KDR NOSTRIN	1.23e-04	185	116	5	f5e14181f45c37d13ee9e017a4c8bc248c353676
ToppCell	COVID-19_Convalescent-CD8+_T_naive\|COVID-19_Convalescent / Disease condition and Cell class	EIF3E MLXIP CD8B CD8B2 OXNAD1	1.23e-04	185	116	5	2f8277a0b58fb0c49fa76ff6dfa6da961da1f9f5
ToppCell	PCW_13-14-Endothelial-Endothelial_mature-lymphatic-endo_lymphatic_(7)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	DOCK9 PECAM1 KIAA1671 NLGN4X KDR	1.23e-04	185	116	5	3be9e05b929ac4d956b1d53284072f668a6c1959
ToppCell	Control-T_cells-NK_cells\|Control / group, cell type (main and fine annotations)	NLRP7 PPP2R5C PLCB1 PIK3R5 SORL1	1.23e-04	185	116	5	755c0998c729f462399f1d5e88adf4bfae31be30
Disease	Malignant neoplasm of breast	STRBP STXBP4 LRRC37A2 PTHLH STAT3 NCOR1 LRRC37A BRCA1 BRCA2 SYNJ2 HEATR9 PLCB1 KDR GPNMB DNAH9 SORL1	2.12e-06	1074	109	16	C0006142
Disease	Mammary Carcinoma, Human	STXBP4 LRRC37A2 PTHLH STAT3 NCOR1 LRRC37A BRCA1 BRCA2 SYNJ2 KDR GPNMB	4.07e-06	525	109	11	C4704874
Disease	Mammary Neoplasms, Human	STXBP4 LRRC37A2 PTHLH STAT3 NCOR1 LRRC37A BRCA1 BRCA2 SYNJ2 KDR GPNMB	4.07e-06	525	109	11	C1257931
Disease	Mammary Neoplasms	STXBP4 LRRC37A2 PTHLH STAT3 NCOR1 LRRC37A BRCA1 BRCA2 SYNJ2 KDR GPNMB	4.22e-06	527	109	11	C1458155
Disease	Breast Carcinoma	STXBP4 LRRC37A2 PTHLH STAT3 NCOR1 LRRC37A BRCA1 BRCA2 SYNJ2 KDR GPNMB	5.13e-06	538	109	11	C0678222
Disease	Albright's hereditary osteodystrophy (implicated_via_orthology)	PTHLH GNAS	1.35e-05	2	109	2	DOID:0080053 (implicated_via_orthology)
Disease	ductal carcinoma in situ (biomarker_via_orthology)	BRCA1 BRCA2	1.35e-05	2	109	2	DOID:0060074 (biomarker_via_orthology)
Disease	Hereditary site-specific ovarian cancer syndrome	BRCA1 BRCA2	1.35e-05	2	109	2	C4749652
Disease	Pancreatic Neoplasm	PTHLH STAT3 BRCA1 BRCA2 KDR	3.57e-05	100	109	5	C0030297
Disease	Malignant neoplasm of pancreas	PTHLH STAT3 BRCA1 BRCA2 KDR	3.93e-05	102	109	5	C0346647
Disease	Colorectal Carcinoma	OMA1 SF3A1 LRRC4 NLGN4X SACS KDR GPNMB GNAS PIK3R5 FAM110B SORL1	5.94e-05	702	109	11	C0009402
Disease	Hereditary breast ovarian cancer syndrome	BRCA1 BRCA2	8.07e-05	4	109	2	cv:C0677776
Disease	neurilemmoma (is_marker_for)	PECAM1 KDR	1.34e-04	5	109	2	DOID:3192 (is_marker_for)
Disease	hereditary breast ovarian cancer syndrome (is_implicated_in)	BRCA1 BRCA2	1.34e-04	5	109	2	DOID:5683 (is_implicated_in)
Disease	Adult only	BRCA1 BRCA2	2.01e-04	6	109	2	C3842001
Disease	Neoplasm of uncertain or unknown behavior of breast	NCOR1 BRCA1 BRCA2	4.72e-04	41	109	3	C0496956
Disease	Breast adenocarcinoma	NCOR1 BRCA1 BRCA2	4.72e-04	41	109	3	C0858252
Disease	Pancreatic carcinoma, familial	BRCA1 BRCA2	4.79e-04	9	109	2	C2931038
Disease	pterygium (is_marker_for)	PECAM1 KDR	4.79e-04	9	109	2	DOID:0002116 (is_marker_for)
Disease	dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 measurement	SIGLEC14 SIGLEC5	5.97e-04	10	109	2	EFO_0801544
Disease	Fanconi anemia (is_implicated_in)	BRCA1 BRCA2	5.97e-04	10	109	2	DOID:13636 (is_implicated_in)
Disease	response to hydrochlorothiazide, fasting blood glucose measurement	JADE1 PCDH15 PHF10	6.63e-04	46	109	3	EFO_0004465, EFO_0005202
Disease	psoriatic arthritis (is_implicated_in)	PECAM1 STAT3	7.28e-04	11	109	2	DOID:9008 (is_implicated_in)
Disease	sialic acid-binding Ig-like lectin 14 measurement	SIGLEC14 SIGLEC5	8.71e-04	12	109	2	EFO_0008284
Disease	Benign tumor of pancreas	BRCA1 BRCA2	1.03e-03	13	109	2	C0347284
Disease	ovarian cancer (is_implicated_in)	STAT3 BRCA1 BRCA2	1.18e-03	56	109	3	DOID:2394 (is_implicated_in)
Disease	Hereditary Breast and Ovarian Cancer Syndrome	BRCA1 BRCA2	1.20e-03	14	109	2	C0677776
Disease	caffeine measurement	PTHLH MEGF11	1.38e-03	15	109	2	EFO_0021177
Disease	Uremia	KDR VCAM1	1.77e-03	17	109	2	C0041948
Disease	MYELODYSPLASTIC SYNDROME	BRCA1 BRCA2 PLCB1	1.98e-03	67	109	3	C3463824
Disease	Pancreatic carcinoma	BRCA1 BRCA2	2.22e-03	19	109	2	C0235974
Disease	Usual Interstitial Pneumonia	STAT3 PARN	2.22e-03	19	109	2	C4721509
Disease	Hamman-Rich Disease	STAT3 PARN	2.22e-03	19	109	2	C4721508
Disease	Adenocarcinoma of prostate	BRCA1 BRCA2	2.46e-03	20	109	2	C0007112
Disease	Familial Idiopathic Pulmonary Fibrosis	STAT3 PARN	2.46e-03	20	109	2	C4721952
Disease	BREAST CANCER	BRCA1 BRCA2	2.71e-03	21	109	2	114480
Disease	Idiopathic Pulmonary Fibrosis	STAT3 PARN	2.71e-03	21	109	2	C1800706
Disease	retinal vasculature measurement	STRBP GARS1 EIF3E XIRP2 PLCB1 NOSTRIN DNAH9	3.12e-03	517	109	7	EFO_0010554
Disease	lateral orbital frontal cortex volume measurement	OMA1 OXNAD1	3.54e-03	24	109	2	EFO_0010312
Disease	lung non-small cell carcinoma (is_marker_for)	PECAM1 STAT3 BRCA1 KDR	3.62e-03	169	109	4	DOID:3908 (is_marker_for)

Protein segments in the cluster

Peptide	Gene	Start	Entry
TVTEIVKQQDPLVYK	ACSBG2	591	Q5FVE4
ELQEKETPTQVYQKD	CEP170	676	Q5SW79
VYQQKVEDVVLPEKV	PRMT2	191	P55345
PKEVINGNIKTVTEY	EIF3G	56	O75821
EEVLQEYQKIKQSSP	ELL2	591	O00472
PYVVVKSTSEEKNNQ	CCDC33	261	Q8N5R6
VPIAQVKDVYVVTDQ	GPNMB	221	Q14956
VKIENLAKANPQYTV	PPP2R5C	431	Q13362
TKVNYVVQEAIVVIK	AP1B1	401	Q10567
IQQLVPEYKEKQTPE	CCDC144CP	116	Q8IYA2
IQQLVPEYKEKQTPE	CCDC144NL	116	Q6NUI1
VILDISNYTPQKVKQ	AHDC1	1141	Q5TGY3
NCVYEVQQVPKVEKT	ANGEL2	406	Q5VTE6
SVNVENQIKIKIYIS	ARMC10	166	Q8N2F6
TTEQPKKNRITYSQI	CHM	206	P24386
QYTNTKLEVKKIPQE	RBM27	596	Q9P2N5
KEQRVYQEATKEVPT	OTOR	106	Q9NRC9
SQPEQVKIAVNTSKY	PARN	486	O95453
VNEKISVQAYETQVK	PM20D1	466	Q6GTS8
QQQQSPVKKERIKYS	C8orf88	66	P0DMB2
AKVYTVNNVNVITKI	ANKRD13A	266	Q8IZ07
DKKIVIYVQQTTNKE	RABGAP1	326	Q9Y3P9
KNIYEVEPTVSVVQE	MEGF11	986	A6BM72
QVPVIESYEKPISQK	KLF3	181	P57682
KKVVPQLRVYQGVTN	LRRC37A3	576	O60309
TYQIPNTQKAKGVVL	KIAA1671	1031	Q9BY89
KKVVPQLRVYQGVTN	LRRC37A2	576	A6NM11
KKVVPQLRVYQGVTN	LRRC37A	576	A6NMS7
YVSPVNTVKNVVTKN	LRIF1	231	Q5T3J3
VVTKNFQNIYPKPVT	LRIF1	241	Q5T3J3
YQTDLKEIPVVIFKN	LRRIQ4	126	A6NIV6
EQQTYQVIPEVIKNF	EIF3L	41	Q9Y262
IIVQKIQPYTEQSTK	KIAA0319L	826	Q8IZA0
EINIEVYSLVQKKDP	ANLN	876	Q9NQW6
ATKINEKPQVIADYE	EDF1	96	O60869
IINEISFTTKVPQKY	KRT222	176	Q8N1A0
VPQKYENENVETVTK	KRT222	186	Q8N1A0
PIIYGIKTKQIQEQV	OR52B4	291	Q8NGK2
DTKPQVQTKEVVQEI	PPL	1281	O60437
VIVNNKEKTTAEYQV	PECAM1	111	P16284
VKQVTNVFITKTYPN	ENPP5	61	Q9UJA9
LRAQKPTVEYKEVTQ	EVPL	1241	Q92817
KQKLQSQYFPDSVIV	DNAJC28	171	Q9NX36
EPYIIQTHTKDKVQE	LRRC4	636	Q9HBW1
KEDQQTVLKPQFYEI	NOL10	581	Q9BSC4
RENVVFVQTDKPTYK	OVOS2	106	Q6IE36
PYPSEEQKKQLVQDT	MEIS3P2	271	A8K0S8
TKQTTQINAELKPYI	OXNAD1	246	Q96HP4
KPKQTQAAEYNRVVS	OR9A1P	261	Q8NGU1
QNTQKVEASKVPEYI	PHF10	186	Q8WUB8
KTVEYITKLQQERGQ	MLXIP	761	Q9HAP2
KNYKELIQQTITPAT	NLGN4Y	321	Q8NFZ3
VPSKSNTAKVYIEIQ	PCDH15	1121	Q96QU1
PEIKKQEYEEVVQTV	BRCA1	1106	P38398
KIVEPYNKIVARTAQ	COG5	151	Q9UP83
VPKYRIQATEIAKQQ	DNAJC25	181	Q9H1X3
QTQVKENKTQPPVAY	ERVK-19	196	Q9YNA8
QTQVKENKTQPPVAY	ERVK-21	196	P62683
QTQVKENKTQPPVAY	ERVK-5	196	Q9HDB9
VLQQTPAYIKVQTNK	CD8B2	21	A6NJW9
DYQPIKKNVTKQIAE	IFT74	571	Q96LB3
PLDYENVIVQKKTQI	DOCK9	51	Q9BZ29
KKTQYQQLPVSDEIL	BRCA2	3031	P51587
VLQQTPAYIKVQTNK	CD8B	21	P10966
IQQLVPEYKEKQTPE	CCDC144B	116	Q3MJ40
KIDVIKQADYVPSDQ	GNAS	181	P63092
IKLYAVEKNPNAVVT	PRMT5	386	O14744
NAVSPYQQVIEKTKS	EIF3E	396	P60228
KQNRVIYKPIVEKEN	ESCO2	166	Q56NI9
YVKSQEVINAKQEPV	FAM110B	61	Q8TC76
KELAYDAQKIPNVVQ	DNAH9	1551	Q9NYC9
IQQLVPEYKEKQTPE	CCDC144A	116	A2RUR9
KRQLKDIPVQQITYT	SACS	2791	Q9NZJ4
KNYKELIQQTITPAT	NLGN4X	321	Q8N0W4
SRYVSPEQKKEIVTQ	PRAMEF26	151	H0Y7S4
VPVFTVEVKNYGVKN	IFNGR1	56	P15260
FIKIPYVQSEEQKEI	KIF2B	581	Q8N4N8
VKPKQTQGVEYNKIV	OR9A2	256	Q8NGT5
EAIKPTYQVLNVQEK	NOSTRIN	96	Q8IVI9
TEAKQELITYPQPQK	RBM6	566	P78332
VLKPDTTYQVKVQVQ	SORL1	1616	Q92673
RQAVKELQVYISPKN	VCAM1	211	P19320
KYKPVVLTDDQVDQA	TIMM29	216	Q9BSF4
KPYNVKQIKTTNAQE	SYNJ2	1161	O15056
QEKLQTYQPEVVKAN	NCOR1	1986	O75376
FQKTLYVEEVVPNVI	GARS1	561	P41250
QEKPVYELQVQKSVT	SIGLEC5	16	O15389
PIQIQKLTEEKYQVE	STRBP	126	Q96SI9
LQKVEIKNVTPDTAY	NLRP7	706	Q8WX94
NKVINSVDIKQSRPY	WDR1	146	O75083
IKVNYNQTAVKVPTT	JADE1	726	Q6IE81
KVQAQVIQETIVPKE	SF3A1	131	Q15459
EIKTGYNKTVQIPIT	STXBP4	166	Q6ZWJ1
IQKQEQIPLTYIVEK	OMA1	506	Q96E52
VKVVQYLVKEVNQFP	ANKHD1	1371	Q8IWZ3
PNIIKNDSETVYKRQ	COL24A1	291	Q17RW2
GKYHQVKTVQQEEIV	XIRP2	821	A4UGR9
RYVSPEQKKEIVTQF	PRAMEF6	246	Q5VXH4
NNYIPDSIQIKVKDV	VWDE	406	Q8N2E2
IENVVLVVPVKTKYN	XPNPEP1	536	Q9NQW7
KNSEEQYNKIVIPNE	MTREX	606	P42285
QYNKIVIPNEESVVI	MTREX	611	P42285
ESKKQLIEPVQYDEQ	MRPS9	251	P82933
QILQKTREVQEKGTY	PIK3R5	61	Q8WYR1
ELQQKVSYKGDPIVQ	STAT3	286	P40763
KTQIQSVEPYTKQQL	STAT3	631	P40763
LQQVAQTGPEKVKYE	HEATR9	186	A2RTY3
RYVSPEQKKEIVTQF	PRAMEF5	246	Q5TYX0
SKQVVPFVYQTIVKD	XRN1	821	Q8IZH2
VDQPQVSYKEADLQK	ZDBF2	1466	Q9HCK1
IVQSQPVEVIYDAKT	VPS13C	626	Q709C8
VVIPSDQVQKKIIVY	USF3	136	Q68DE3
QETNKVETYKEQPLK	PTHLH	106	P12272
LKQEQVQVLIEKYEP	PLCB1	266	Q9NQ66
QKPEVDQQIVIYTKG	TSPAN5	206	P62079
KVINQYQVVKPTAER	USP10	771	Q14694
IEKQVKTVRFQNYSP	SH3RF2	636	Q8TEC5
LNPDVYTKNKQQIVI	TAS2R8	71	Q9NYW2
VYITENKNKTVVIPC	KDR	136	P35968
LQIKPKQTTEFYEQE	TRRAP	2721	Q9Y4A5
QEKPVYELQVQKSVT	SIGLEC14	16	Q08ET2
KNYIKNQVVRLTPEE	TMPRSS11A	96	Q6ZMR5
QEDIKADKVTQLYVP	UBE3C	631	Q15386
QVSSKVPYEIQKGQA	NMI	91	Q13287